DK0988862T3 - Formulering indeholdende et antigen, en TH-1 inducerende adjuvant og en sparsomt vandoplöselig aminosyre til brug ved immunisering - Google Patents

Formulering indeholdende et antigen, en TH-1 inducerende adjuvant og en sparsomt vandoplöselig aminosyre til brug ved immunisering

Info

Publication number
DK0988862T3
DK0988862T3 DK99307406T DK99307406T DK0988862T3 DK 0988862 T3 DK0988862 T3 DK 0988862T3 DK 99307406 T DK99307406 T DK 99307406T DK 99307406 T DK99307406 T DK 99307406T DK 0988862 T3 DK0988862 T3 DK 0988862T3
Authority
DK
Denmark
Prior art keywords
antigen
amino acid
immunization
formulation containing
soluble amino
Prior art date
Application number
DK99307406T
Other languages
English (en)
Inventor
Alan Wheeler
Anthony Berry
Original Assignee
Allergy Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergy Therapeutics Ltd filed Critical Allergy Therapeutics Ltd
Application granted granted Critical
Publication of DK0988862T3 publication Critical patent/DK0988862T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK99307406T 1998-09-21 1999-09-17 Formulering indeholdende et antigen, en TH-1 inducerende adjuvant og en sparsomt vandoplöselig aminosyre til brug ved immunisering DK0988862T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9820525.5A GB9820525D0 (en) 1998-09-21 1998-09-21 Formulation

Publications (1)

Publication Number Publication Date
DK0988862T3 true DK0988862T3 (da) 2006-12-27

Family

ID=10839197

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99307406T DK0988862T3 (da) 1998-09-21 1999-09-17 Formulering indeholdende et antigen, en TH-1 inducerende adjuvant og en sparsomt vandoplöselig aminosyre til brug ved immunisering

Country Status (13)

Country Link
US (2) US6440426B1 (da)
EP (1) EP0988862B1 (da)
JP (2) JP4743928B2 (da)
KR (1) KR100642877B1 (da)
AT (1) ATE346610T1 (da)
AU (1) AU766251B2 (da)
CA (1) CA2282779C (da)
DE (1) DE69934179T2 (da)
DK (1) DK0988862T3 (da)
ES (1) ES2277413T3 (da)
GB (2) GB9820525D0 (da)
NZ (1) NZ337885A (da)
PT (1) PT988862E (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6380376B1 (en) * 1992-10-30 2002-04-30 Iowa State University Research Foundation Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US20010026800A1 (en) * 2000-01-07 2001-10-04 Michael Jacob G. Selective activation of a TH1 or TH2 lymphocyte regulated immune response
GB0000891D0 (en) 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
JP5175417B2 (ja) * 2000-08-17 2013-04-03 トリペップ アクチ ボラゲット リバビリンを含むワクチンおよびその使用方法
US6858590B2 (en) * 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US6680059B2 (en) * 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
AU2002213441B2 (en) * 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
EP1366126B1 (de) * 2001-01-30 2007-05-30 Schwan-STABILO Schwanhäusser GmbH & Co. KG Markierungsflüssigkeit
DE10125731A1 (de) * 2001-05-17 2003-03-06 A I D Autoimmun Diagnostika Gm Darreichungsform von immunologischen Wirkstoffen
US20050158303A1 (en) * 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
MXPA05010555A (es) 2003-04-04 2006-03-09 Genentech Inc Formulaciones de proteina y anticuerpo de alta concentracion.
US8333976B2 (en) * 2003-08-28 2012-12-18 Sandor Sipka Processes for inhibiting development of allergic disease
CA2596920C (en) * 2005-01-28 2015-05-05 North-West University Lipid and nitrous oxide combination as adjuvant for the enhancement of the efficacy of vaccines
CA2618429A1 (en) * 2005-05-25 2007-03-22 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
US8071561B2 (en) * 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
US20090214593A1 (en) * 2007-08-16 2009-08-27 Tripep Ab Immunogen platform
AU2010221156A1 (en) * 2009-03-06 2011-09-22 Genentech, Inc. Antibody formulation
PT3345615T (pt) 2010-03-01 2020-01-17 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
GB201106802D0 (en) 2011-04-21 2011-06-01 Allergy Therapeutics Ltd Process for preparing vaccine composition
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
WO2015050181A1 (ja) * 2013-10-03 2015-04-09 日東電工株式会社 注射ワクチン組成物

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1128637A (en) 1966-09-13 1968-09-25 Beecham Group Ltd Influenza vaccine
US3541201A (en) * 1968-12-18 1970-11-17 Ethan Alan Brown Novel sodium chloride encapsulated injectionable substances
GB1377074A (en) 1971-07-13 1974-12-11 Beecham Group Ltd Process for preparing injectable compositions
GB1492973A (en) 1974-02-16 1977-11-23 Beecham Group Ltd Process for preparing injectable compositions
US4070455A (en) 1974-02-16 1978-01-24 Beecham Group Limited Process for preparing injectable desensitizing compositions and products thereof in microparticle form
EP0182442B2 (en) 1978-12-22 1996-04-03 Biogen, Inc. Recombinant DNA molecules and their method of production
US4258029A (en) 1979-04-23 1981-03-24 Connaught Laboratories Limited Synthetic adjuvants for stimulation of antigenic responses
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5244663A (en) 1987-01-28 1993-09-14 Medibrevex Therapeutic method against allergy
FR2621916B1 (fr) * 1987-10-19 1990-03-09 Bioeurope Derives de la l-tyrosine solubles dans l'eau et procede pour leur preparation
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB9106048D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccines
US5338543A (en) * 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
RU94040856A (ru) 1992-03-03 1996-08-20 Дайити Фармасьютикал Ко. Вакцина для перорального введения
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
CA2156525A1 (en) * 1993-02-19 1994-09-01 Susan Dillon Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
US5776468A (en) * 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
US5958457A (en) * 1993-04-22 1999-09-28 Emisphere Technologies, Inc. Compositions for the delivery of antigens
DE69426077T3 (de) 1993-05-25 2004-09-02 Wyeth Holdings Corp. Adjuvantien für impfstoffe gegen das respiratorische synzitialvirus
JPH09502604A (ja) 1993-08-27 1997-03-18 エンテリック リサーチ ラボラトリーズ インコーポレイテッド Ｃａｍｐｙｌｏｂａｃｔｅｒｊｅｊｕｎｉ抗原、並びにそれらの製造及び利用
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5646115A (en) 1994-10-07 1997-07-08 Heska Corporation Ectoparasite saliva proteins and apparatus to collect such proteins
AU4977896A (en) 1995-02-17 1996-09-04 Immunotherapy, Inc. Immunotherapy screening, prognosis, and treatment methods and compositions
GB9508785D0 (en) 1995-04-29 1995-06-21 Smithkline Beecham Plc Novel compositions
US5762943A (en) 1996-05-14 1998-06-09 Ribi Immunochem Research, Inc. Methods of treating type I hypersensitivity using monophosphoryl lipid A
US5973128A (en) 1996-11-22 1999-10-26 The Hospital For Sick Children Research And Development Lp Glycolipid mimics and methods of use thereof
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
CN1326564C (zh) 1997-04-01 2007-07-18 科里克萨有限公司 单磷酰基脂质a的水性免疫佐剂组合物
GB9706957D0 (en) * 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
AU7983198A (en) 1997-06-23 1999-01-04 Ludwig Institute For Cancer Research Improved methods for inducing an immune response
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
CA2319380A1 (en) 1997-11-10 1999-05-20 Statens Serum Institut Nucleic acid fragments and polypeptide fragments derived from m. tuberculosis
GB9812613D0 (en) * 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
EP1086228A1 (en) * 1998-06-12 2001-03-28 SMITHKLINE BEECHAM BIOLOGICALS s.a. Recombinant production of toxoplasma sag1 antigen
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US6734172B2 (en) 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
SI1031347T1 (en) 1999-01-27 2002-10-31 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
WO2000050078A1 (en) 1999-02-26 2000-08-31 Chiron Corporation Use of bioadhesives and adjuvants for the mucosal delivery of antigens
GB9909077D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
HUP0200958A3 (en) 1999-04-23 2004-11-29 Pharmexa As Method for down-regulating il5 activity
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
GB9924529D0 (en) 1999-10-15 1999-12-15 Smithkline Beecham Biolog Novel compounds
GB0000891D0 (en) 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation

Also Published As

Publication number Publication date
AU4877799A (en) 2000-06-08
NZ337885A (en) 2001-01-26
AU766251B2 (en) 2003-10-09
KR100642877B1 (ko) 2006-11-13
JP2000103745A (ja) 2000-04-11
JP4743928B2 (ja) 2011-08-10
GB2341801B (en) 2003-10-29
CA2282779C (en) 2011-02-01
GB9922121D0 (en) 1999-11-17
EP0988862B1 (en) 2006-11-29
US6440426B1 (en) 2002-08-27
US7815920B2 (en) 2010-10-19
JP2010265330A (ja) 2010-11-25
ES2277413T3 (es) 2007-07-01
DE69934179D1 (de) 2007-01-11
CA2282779A1 (en) 2000-03-21
GB9820525D0 (en) 1998-11-11
KR20000023273A (ko) 2000-04-25
EP0988862A2 (en) 2000-03-29
ATE346610T1 (de) 2006-12-15
US20030007977A1 (en) 2003-01-09
EP0988862A3 (en) 2001-06-20
GB2341801A (en) 2000-03-29
DE69934179T2 (de) 2007-04-19
PT988862E (pt) 2007-01-31

Similar Documents

Publication Publication Date Title
DK0988862T3 (da) Formulering indeholdende et antigen, en TH-1 inducerende adjuvant og en sparsomt vandoplöselig aminosyre til brug ved immunisering
NO20020532D0 (no) Farmasöytiske preparater inneholdende beta-carbolin
NO991130D0 (no) Modifiserte aminosyrer, farmas°ytiske preparater som inneholder disse forbindelsene og fremgangsmÕter for fremstilling derav
DE69524981D1 (de) Pharmazeutische Zubereitungen enthaltend Raloxifen, einen oberflächenaktiven Stoff und ein wasserlösliches Verdünnungsmittel
DK1140165T3 (da) Fordbedrede adjuvanssammensætninger baseret på saponin og dermed tilhörende metoder
ES2151476T3 (es) Formulaciones de farmacos en aerosol.
NO20005224D0 (no) BTK inhibitorer og fremgangsmÕter for deres identifikasjon og anvendelse
NZ319377A (en) polypeptides comprising a portion of a soluble M tuberculosis antigen
DK0698393T3 (da) 3-/-menthoxypropan-1,2-diol som solubiliseringsmiddel og præparat til udvortes brug, der indeholder samme
BR9906927A (pt) Proteìnas de neisseria meningitidis
DK0734720T3 (da) Partikler baseret på polyaminosyre(r) til anvendelse som bærere for aktive midler og fremgangsmåder til fremstilling deraf
NO20021424D0 (no) Granuler basert på stivelse og laktose
EP1181937A3 (en) Novel vaccine adjuvant and vaccine
NO985464L (no) Konsentrert antistoffpreparat
DK0765333T3 (da) Quillajasaponinadjuvans og vaccineformulering, der indeholder denne
NO972451L (no) Heterosyklyloksy- og tiometyl-1,2,5-tiadiazolidin-3-on 1,1-dioksyder og preparater og fremgangsmåte for anvendelse derav
NO980178D0 (no) Cyklo-oksygenase-inhibitor og amidin-derivatsalter, fremgangsmåte for fremstilling derav, anvendelse derav som legemidler, og farmasöytiske blandinger inneholdende slike derivater
NO20003119D0 (no) Aminobiguanider for desinfeksjon av kontaktlinser og preservering av farmasøytiske preparater
DE69637947D1 (de) Multimerer, rekombinanter urease impfstoff
TR24956A (tr) TABLET SEKLINE PESTISID FORMüLASYONLARI
ATE169637T1 (de) Derivate des dolastatin
DK0567100T3 (da) Respiratorisk syncytial virus (RSV)-mutant og farmaceutisk præparat indeholdende en sådan mutant
DK0975360T3 (da) Bovint respiratorisk og enterisk coronavirus som vaccine
AP9901666A0 (en) Leishmania vaccine.
GB9930768D0 (en) Composition